Skip to main content
. 2021 Nov 3;13(21):5516. doi: 10.3390/cancers13215516

Figure 5.

Figure 5

TP-472 treatment leads to downregulation of several ECM proteins in melanoma cells. A375 cells were treated with DMSO, 5 μM TP-472, or 10 μM TP-472 for 24 h, after which RNA sequencing was performed. (A). Heatmap showing the several ECM genes that were downregulated after 5 μM, or 10 μM of TP-472 treatment. (B). A375 cell line was treated with 10 μM of TP-472 for 24 h. Immunoblotting was performed to measure protein expression of the shown candidates. ACTINB were measured as loading controls. (C). Indicated ECM proteins were analyzed using Oncomine-Talantov melanoma patient dataset. All significantly altered ECM genes in melanoma samples versus normal skin samples are shown. Many of the ECM proteins have direct pharmacological targets and can be either targeted alone (box highlighted in yellow color) or in combination (based on the significant co-expression with BRD7) with TP-472 (box highlighted in orange color).